| Literature DB >> 29413083 |
Paul J Wolters1, Timothy S Blackwell2, Oliver Eickelberg3, James E Loyd2, Naftali Kaminski4, Gisli Jenkins5, Toby M Maher6, Maria Molina-Molina7, Paul W Noble8, Ganesh Raghu9, Luca Richeldi10, Marvin I Schwarz3, Moises Selman11, Wim A Wuyts12, David A Schwartz3.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and typically fatal lung disease characterised by subpleural fibrosis, subepithelial fibroblast foci, and microscopic honeycombing. Although understanding of the pathogenic mechanisms continues to evolve, evidence indicates that distal airway and alveolar epithelial cells are central drivers of the disease. In this Viewpoint, we review the history of naming and classifications used to define the disease now referred to as IPF, in the context of understanding the clinical presentation, causes, and pathogenesis of the disease. We aim to generate discussion on whether, given the substantial progress made in understanding the clinical, genetic, cellular, and molecular mechanisms involved in the development of IPF, a change of name should be considered. To initiate this discussion, we offer new suggestions to update the name of this disease and new approaches to classify all forms of pulmonary fibrosis.Entities:
Mesh:
Year: 2018 PMID: 29413083 PMCID: PMC5903445 DOI: 10.1016/S2213-2600(18)30007-9
Source DB: PubMed Journal: Lancet Respir Med ISSN: 2213-2600 Impact factor: 30.700